bristol-myers glp-1 receptor agonist products Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Agonists: A Multidisciplinary Expert Consensus GLP-ONE + Receptor Activator |
Description
Expand into niche indications: Tap into segments where small molecules are less competitive, such as NASH, Alzheimers disease and cardiovascular protection
[DOI] [PMC free article] [PubMed] [Google Scholar] 50.Tuesta L.M., Chen Z., Duncan A., Fowler C.D., Ishikawa M., Lee B.R., Liu X.-A., Lu Q., Cameron M., Hayes M.R., et al
The individual tolerability and severity of gastrointestinal symptoms at the beginning of therapy are heterogeneous (36)
Injectable vs
2024 Sep 18;9(1):234
These payer mechanisms reflect limited public reimbursement coverage for obesity pharmacotherapy under the National Health Insurance system
